5.27 USD
+0.1 (+1.93%)
5.2539 USD
-0.02 (-0.31%)
ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
ORGO had a negative operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ORGO has a better Return On Assets (-2.63%) than 87.33% of its industry peers.
ORGO has a better Return On Equity (-3.47%) than 89.22% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.16%, ORGO belongs to the top of the industry, outperforming 88.66% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROIC | 0.16% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO has a Operating Margin of 0.18%. This is amongst the best in the industry. ORGO outperforms 88.85% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 74.49%, ORGO belongs to the top of the industry, outperforming 83.18% of the companies in the same industry.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ORGO is destroying value.
ORGO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
ORGO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.52 indicates that ORGO is not in any danger for bankruptcy at the moment.
ORGO has a better Altman-Z score (4.52) than 71.64% of its industry peers.
ORGO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ORGO's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. ORGO outperforms 45.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.52 |
ROIC/WACC0.02
WACC8.9%
2.3 Liquidity
A Current Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.32, ORGO is doing worse than 61.06% of the companies in the same industry.
A Quick Ratio of 2.88 indicates that ORGO has no problem at all paying its short term obligations.
With a Quick ratio value of 2.88, ORGO is not doing good in the industry: 64.84% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.91%.
ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -37.90% yearly.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 2.24%.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 29.27% on average per year.
The Revenue is expected to grow by 8.70% on average over the next years. This is quite good.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 527.00, the valuation of ORGO can be described as expensive.
88.66% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
ORGO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.22.
The Price/Forward Earnings ratio is 35.63, which means the current valuation is very expensive for ORGO.
91.87% of the companies in the same industry are more expensive than ORGO, based on the Price/Forward Earnings ratio.
ORGO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.58.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 527 | ||
| Fwd PE | 35.63 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 92.06% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 31.95 |
4.3 Compensation for Growth
ORGO has a very decent profitability rating, which may justify a higher PE ratio.
ORGO's earnings are expected to grow with 29.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.27
+0.1 (+1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners54.82%
Inst Owner Change-1.32%
Ins Owners31.5%
Ins Owner Change-0.26%
Market Cap668.82M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (64.52%)
Short Float %16.05%
Short Ratio6.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)6.25%
PT rev (3m)6.25%
EPS NQ rev (1m)35.48%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)216.67%
EPS NY rev (3m)450%
Revenue NQ rev (1m)3.66%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)5.49%
Revenue NY rev (3m)5.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 527 | ||
| Fwd PE | 35.63 | ||
| P/S | 1.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.73 | ||
| P/tB | 1.93 | ||
| EV/EBITDA | 31.95 |
EPS(TTM)0.01
EY0.19%
EPS(NY)0.15
Fwd EY2.81%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.19% | ||
| ROICexgc | 0.21% | ||
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 70.73% | ||
| Cap/Sales | 2.76% | ||
| Interest Coverage | 0.99 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | 4.52 |
F-Score2
WACC8.9%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
What is the valuation status for ORGO stock?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
How profitable is ORGANOGENESIS HOLDINGS INC (ORGO) stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.
What is the valuation of ORGANOGENESIS HOLDINGS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ORGANOGENESIS HOLDINGS INC (ORGO) is 527 and the Price/Book (PB) ratio is 1.73.
Can you provide the expected EPS growth for ORGO stock?
The Earnings per Share (EPS) of ORGANOGENESIS HOLDINGS INC (ORGO) is expected to decline by -58% in the next year.